Last Updated: July 09, 2026
When Phase II extends 18 months past projections, marketing plans collapse. When physicians need peer-reviewed evidence, traditional B2B playbooks fail. We embed fractional CXOs who know how to build commercial readiness around clinical reality.
The Problem
Clinical timelines destroy commercial roadmaps
Most biotech marketing teams build campaigns against projected approval dates. When Phase II extends 12-18 months, the entire commercial roadmap breaks. Investor updates, commercial team hiring, and KOL engagement programs all depend on timing signals the clinical team cannot reliably give you. You end up rebuilding the plan quarterly while competitors who launched earlier consolidate physician relationships.
FDA promotional restrictions make pre-approval marketing a compliance minefield
You cannot make efficacy claims about investigational products. Every piece of promotional content requires legal review, and legal teams trained on compliance – not conversion – slow everything down. The result is a marketing function that is reactive rather than strategic. Companies that crack this build compliant awareness programs around disease education and unbranded content; most do not know where to start and default to doing nothing.
Physician adoption requires evidence standards most marketing teams cannot meet
Doctors are not enterprise software buyers. Clinical validation, peer influence, and published outcomes drive adoption decisions far more than awareness campaigns. A marketing team trained on B2B demand generation will run LinkedIn ads to physicians and wonder why conversion is zero. Building physician adoption programs requires fluency in clinical evidence hierarchies, KOL mapping, and medical affairs alignment that generalist marketers simply do not have.
How We Help
We embed fractional CXOs who understand FDA promotional guidelines, clinical evidence requirements, and the commercial realities of life sciences. Your fractional leader builds the growth strategy around regulatory constraints – not despite them.
The first 30 days are diagnostic: full commercial audit against FDA promotional guidance, clinical milestone mapping, and stakeholder interviews across medical affairs, regulatory, and commercial teams. We do not start executing until we know what is broken and what is actually working.
Days 30-60 shift to structure. Compliant pre-launch awareness frameworks, physician evidence programs tied to your clinical data, and KOL engagement strategies built around peer influence rather than cold outreach. We build the measurement infrastructure so every dollar spent during clinical development connects to a commercial objective – not a vanity metric.
By day 90, you have a functioning commercial readiness engine. FDA-compliant processes, milestone-aligned plans, and physician adoption frameworks that do not collapse when a trial extends. If your timeline shifts, the plan adapts rather than starting over.
What separates this from traditional consulting is accountability. We own the commercial number, attend leadership meetings, manage vendor relationships, and make real resource allocation calls. The fractional model gives you senior life sciences expertise without the 4-6 month recruiting cycle for a full-time hire who actually knows FDA promotional compliance.
What we deliver
- FDA promotional compliance audit and framework
- Clinical timeline-aligned commercial roadmap
- Physician KOL mapping and evidence adoption program
- Pre-launch compliant awareness strategy
- Commercial readiness measurement framework
Most biotech companies treat FDA compliance as a constraint on marketing. The ones that win treat it as a forcing function – it eliminates the noise and pushes you to build physician relationships on evidence, which is the only thing that drives adoption anyway.
Our Methodology
Our 90-day sprint is structured around the reality that biotech timelines shift. Phase one (days 1-30) is diagnostic: FDA compliance review of existing materials, clinical milestone mapping, and stakeholder interviews to find where the handoff between clinical and commercial is broken. We establish baseline metrics before touching anything.
Phase two (days 30-60) is build: compliant pre-launch frameworks, physician evidence adoption programs, KOL engagement infrastructure, and measurement systems tied to clinical milestones rather than arbitrary marketing dates. Everything built here is designed to function whether or not approval comes on schedule.
Phase three (days 60-90) is execution and optimization. Systems are running, the team knows their roles, and we are adjusting based on live data. Monthly strategy presentations to leadership cover what is working, what is not, and where to invest next. By the end of the sprint, you have a commercial engine that is not dependent on us to keep running.
How We Work
In the first 30 days, we audit your commercial infrastructure against FDA promotional guidelines, map clinical milestones to commercial activities, and conduct stakeholder interviews across medical affairs, regulatory, and marketing. We establish baseline metrics before changing anything.
Days 30-60: strategy and early execution. Physician evidence programs, compliant awareness frameworks, and KOL engagement infrastructure go live. Weekly check-ins keep the team aligned; the leadership team gets visibility into the roadmap and resource allocation decisions.
Days 60-90: full execution. We are optimizing based on real data, running physician adoption programs, and adjusting based on what is actually moving. Monthly strategy presentations give leadership a clear picture of progress against commercial milestones.
Engagements typically run 3-6 months at 15-20 hours per week embedded with your team. Extensions are common when companies are approaching approval and need to accelerate commercial readiness before launch.
- FDA compliance confidence across all marketing materials
- Clinical milestone-aligned commercial roadmap
- Physician and KOL adoption infrastructure
- Commercial launch readiness
If your biotech & life sciences company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a fractional CXO cost for a biotech company?
Fractional biotech CXO engagements typically run $22K-$38K per month depending on clinical stage, FDA complexity, and hours required. That compares to $450K or more in total compensation for a full-time life sciences marketing executive with real regulatory and physician adoption experience. The recruiting timeline for that hire is typically 4-6 months – time most clinical-stage companies cannot afford to lose waiting on a search.
How do you handle FDA promotional compliance for biotech marketing?
We audit existing materials against current FDA promotional guidelines, build compliant pre-launch awareness frameworks, and establish review processes that reduce legal bottlenecks without cutting compliance oversight. The goal is marketing that is proactive within regulatory guardrails rather than paralyzed by them. We have built compliant programs for both investigational products in development and approved products entering competitive markets.
What does physician adoption work actually look like in practice?
It starts with KOL mapping – identifying which physicians drive peer influence in your indication and what evidence they need. We build programs around clinical data you already have: peer-to-peer dissemination strategies, medical affairs alignment, and congress presence that reinforces your evidence base. Cold outreach to physicians without evidence backing is a waste of budget. Everything we do connects back to your clinical data as the primary adoption driver.
How long before we see results from a fractional CXO engagement?
FDA compliance gaps and commercial roadmap misalignment surface in the first 30 days. Physician adoption programs and KOL engagement infrastructure are built and running by day 60. Measurable commercial progress – pipeline engagement, evidence program uptake, compliant awareness reach – shows by day 90. The sprint structure is designed to deliver real outputs at every phase, not just at month six when it is too late to course-correct.
What makes Winston Francois different from a life sciences marketing agency?
Agencies execute tactics. We own the commercial number. A fractional CXO from Winston Francois sits in your leadership meetings, makes resource allocation decisions, and is accountable for commercial outcomes – not just deliverable completion. We also build systems your internal team can run after the engagement ends, which is the opposite of the agency dependency model. If your clinical timeline shifts mid-engagement, we adapt the plan – agencies keep executing the scope.
What type of biotech company is the right fit for this engagement?
The best fit is a clinical-stage or recently approved biotech that needs senior commercial leadership but cannot justify a full-time CXO hire yet. Typically Series B through pre-commercial stage with a product in Phase II or later. If you are still in Phase I with no near-term commercial horizon, the engagement is premature. The first step is a 30-minute call to assess where you are in the clinical-to-commercial transition and what the highest-priority gaps are.
